Medical News / Coverage ASRS 2019: Vrinda Hershberger, MD, PhD: Faricimab for Diabetic Macular Edema

An analysis of the phase 2 BOULEVARD trial presented at the 2019 American Society of Retina SpecialistsAnnual Meeting highlighted the anatomical benefits and the potential for extended durability with faricimab compared with anti-VEGF mono therapy in patients with diabetic macular edema (DME). 

 Data from the analyses, which was presented for the first time at ESRS 2019 by Vrinda Hershberger, MD, PhD, found that faricimab not only led to improved best-corrected visual acuity and central subfield thickness from baseline, but also provided anatomical benefits and displayed a potential for extended durability compared to anti-VEGF monotherapy. 

 In between sessions, Hershberger, vitreal retina surgeon with Florida Eye Associates, sat down with MD Magazine at ESRS 2019 to discuss the findings of the analysis and what they mean going forward. 

 Source: MDmag By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization ...

read more

Findings of recent research demonstrate an intervention program, Balance after Baby, is promising for decreasing diabetes ... read more
A new analysis of data from the PIONEER program indicates reductions in HbA1c and body weight ... read more
Findings of a recent study suggest empagliflozin is associated with a decreased risk of hospitalization for ... read more
Testosterone treatment may prevent progression to or reverse type 2 diabetes in high-risk men who are ... read more